March 8, 2023 — Treatments for peripheral artery disease (PAD) were largely developed in men and are less effective in women, according to a review published today in European Heart Journal – Quality of Care and Clinical Outcomes, a journal of the European Society of Cardiology (

March 8, 2023 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech announced today the first cases with its investigationa

March 8, 2023 — B. Hadley Wilson, MD, FACC, is the new president of the American College of Cardiology. Today marks the first day of his one-year term leading the global cardiovascular organization in its mission to transform cardiovascular care and improve heart health. 

March 8, 2023 — A unique community-based partnership, the African American Heart Study, will be conducted to measure the association between Lipoprotein(a), or Lp(a), and atherosclerotic cardiovascular disease (ASCVD) in 5,000 African American individuals across the United States.

March 7, 2023 — People with heart failure were 38% less likely to be readmitted to the hospital for heart failure complications within 90 days if they wore a stick-on sensor that alerted their clinician about fluid buildup in the lungs, according to a study presented at the American College of Cardiology’s Annual Scientific Session Together With the World Congress of Cardiology. 

March 7, 2023 — An experimental wrist-worn device was found to predict troponin-I and obstructed arteries with 90% accuracy in five minutes, according to research being presented at the American College of Cardiology’s Annual Scientific Session Together With the World Congress of Cardiology. 

March 7, 2023 — Ninety-five percent of athletes with a diagnosed and treated genetic heart disease experienced no disease-triggered cardiac events, such as cardiogenic fainting or seizures, implantable cardio-defibrillator (

March 6, 2023 — Patients with pulmonary arterial hypertension (high blood pressure in the arteries that supply the lungs, also called PAH) had approximately double the reduction in pulmonary vascular resistance (PVR) if they took the PAH medications macitentan (10 mg) and tadalafil (40 mg) together in a single tablet rather than either drug alone, according to research being presented at the American College of Cardiology’s Annual Scientific Session Together With the

March 6, 2023 — A multifaceted intervention to improve prescribing practices increased the likelihood that patients with Type 2 diabetes and heart disease would be prescribed three classes of guideline-recommended medications by more than fourfold, according to research being presented at the American College of Cardiology’s Annual Scientific Session Together With the World Congress of Cardiology. 

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now